harboring a BRAF V600E mutation. The trial showed a statistically significant and clinically meaningful improvement in PFS, one of its NEW YORK, January 28, 2025--Pfizer Inc. (NYSE: PFE ...
Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...
NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with $63.6 billion in annual revenue and an impressive 74% gross profit margin, has announced the U.S. Food and Drug Administration's ...
Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...
The leading Metastatic Pancreatic Cancer Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, ...